Clinical Trial Update: Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia

View source ↗

Summary

This document reports on a completed clinical trial evaluating Ribomustin (bendamustine) as first-line therapy for chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ribomustin (bendamustine)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Chronic Lymphocytic Leukemia | Status: COMPLETED